ERBB2 and COVID-19: Tested in combination with trastuzumab and pertuzumab in metastatic trastuzumab-resistant HER2+ breast cancer patients (Phase I: Completed); Under current investigation for treatment of COVID-19 in breast cancer versus non-cancer patients (Phase II); Immunotherapy-based treatment combinations in metastatic or inoperable locally advanced TNBC under current investigation (Phase Ib/II)